Hall, M. J., Rothe, M., Mangat-Dhaliwal, P., Garrett-Mayer, E., Al baghdadi, T., Pisick, E., … Schilsky, R. L. (2025). 943P Atezolizumab plus Talazoparib (A+T) in patients (pts) with solid tumors with BRCA1/2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In Annals of Oncology (Vol. 36, pp. S617–S618). Elsevier BV. https://doi.org/10.1016/j.annonc.2025.08.1512

Hall, M. J., M. Rothe, P. Mangat-Dhaliwal, E. Garrett-Mayer, T. Al baghdadi, E. Pisick, M. Akce, et al. “943P Atezolizumab plus Talazoparib (A+T) in patients (pts) with solid tumors with BRCA1/2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” In Annals of Oncology, 36:S617–18. Elsevier BV, 2025. https://doi.org/10.1016/j.annonc.2025.08.1512.

Hall MJ, Rothe M, Mangat-Dhaliwal P, Garrett-Mayer E, Al baghdadi T, Pisick E, et al. 943P Atezolizumab plus Talazoparib (A+T) in patients (pts) with solid tumors with BRCA1/2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. In: Annals of Oncology. Elsevier BV; 2025. p. S617–8.

Hall, M. J., et al. “943P Atezolizumab plus Talazoparib (A+T) in patients (pts) with solid tumors with BRCA1/2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.” Annals of Oncology, vol. 36, Elsevier BV, 2025, pp. S617–18. Crossref, doi:10.1016/j.annonc.2025.08.1512.

Hall MJ, Rothe M, Mangat-Dhaliwal P, Garrett-Mayer E, Al baghdadi T, Pisick E, Akce M, Cannon T, Meric-Bernstam F, Calfa C, Butler KY, Grigg C, Cobain E, Suryadevara U, Sinclair S, George TJ, Mckean M, Gregory A, Halabi S, Schilsky RL. 943P Atezolizumab plus Talazoparib (A+T) in patients (pts) with solid tumors with BRCA1/2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Annals of Oncology. Elsevier BV; 2025. p. S617–S618.